Lilly to offer all doses of Zepbound vials at $499 or less per month

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a pharmaceutical giant with a market capitalization of $735 billion and an "GREAT" financial health rating according to InvestingPro, announced Monday that the highest approved doses of its obesity medication Zepbound (tirzepatide) will soon be available in single-dose vials for $499 per month through its Self Pay Journey Program, regardless of insurance status.

Healthcare providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, with shipments to patients starting in early August. With these additions, all strengths of Zepbound vials will be available for $499 per month or less, with the 2.5 mg starter dose priced at $349.

Zepbound is an injectable prescription medicine for adults with obesity or overweight with weight-related medical problems. In clinical trials, adults with obesity taking the 15 mg dose lost an average of 48 pounds (approximately 21% of body weight), with about one-third of participants losing more than 58 pounds. This breakthrough product is contributing to Eli Lilly’s impressive 36.4% revenue growth and industry-leading 81.7% gross profit margin over the last twelve months.

The complete range of Zepbound single-dose vials will include 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. While the standard prices for higher doses range from $599 to $1,049, the Self Pay Journey Program reduces the monthly cost to $499 for first fills and refills made within 45 days of prior delivery.

"Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions," said Rhonda Pacheco, group vice president of U.S. Cardiometabolic Health at Lilly.

Zepbound is also available in single-dose pens. The recommended starting dosage is 2.5 mg taken once weekly for four weeks, with potential increases in 2.5 mg increments after at least four weeks on the current dose.

The announcement is based on a press release from Eli Lilly and Company. As a prominent player in the pharmaceuticals industry, Eli Lilly continues to demonstrate strong market performance. For detailed analysis including 13 additional ProTips and comprehensive financial metrics, visit InvestingPro, where you can access the complete Pro Research Report on Eli Lilly and 1,400+ other top stocks.

In other recent news, Eli Lilly has been the focus of several notable developments. UBS has maintained its Buy rating on Eli Lilly, setting a price target at $1,050.00, with particular attention on the upcoming Phase 3 SURPASS-CVOT trial comparing Mounjaro to Trulicity in type 2 diabetes patients. The trial’s results, expected by June 2025, could significantly impact the company’s position in the diabetes treatment market. Meanwhile, TD Cowen adjusted its price target for Eli Lilly to $960 from $1,050, maintaining a Buy rating, as analysts prepare for the upcoming Q3 results of the SURPASS-CVOT trial.

Additionally, Eli Lilly’s recent launch of single-use tirzepatide vials has been highlighted by UBS, noting a trend of patients splitting vials to manage costs, which could influence the company’s pricing strategy. The firm also observed that the upcoming CVS formulary change, favoring Wegovy over Zepbound, may affect Eli Lilly’s market dynamics. Furthermore, Bernstein SocGen Group reiterated an Outperform rating for Eli Lilly, emphasizing the importance of data presentations at the upcoming American Diabetes Association meeting. Eli Lilly is set to present new data on its diabetes and muscle-wasting treatments, which could offer insights into future applications and market strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.